Welcome to Multibagg AI
Log in to access personalized features
Discovery themes featuring this stockGet instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Home
Dashboard
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.
Investor Presentation
Q3 FY26
Investor Presentation
Q4 FY25
Investor Presentation
Q1 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q4 FY24
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Veerhealth Care Ltd (NIYATILEAS) is currently trading at 19.49 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Veerhealth Care Limited is diversified in the pharmaceutical and personal care manufacturing sector, focusing on creating formulations of cosmetics and oral care products. Since 2013, the company has expanded from infrastructure and finance into the pharma sector, clearly defining its scope towards cosmetics and personal care industries. By leveraging ayurvedic expertise, the company aims to develop high-quality herbal products for various applications, utilizing traditional knowledge from its parent company. The company's evolution from financial services to a diverse manufacturing portfolio indicates a strategic shift towards consumer health and wellness products.
Over the past 52 weeks, Veerhealth Care Ltd has traded between a low of ₹9.29 and a high of ₹23.77. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Veerhealth Care Ltd has a market capitalization of approximately 38.78. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Veerhealth Care Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 48.48 and operates in the Pharmaceuticals sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 38.78 Cr, Veerhealth Care Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Veerhealth Care Ltd operates in the Pharmaceuticals sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Veerhealth Care Ltd is 48.48. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
| Symbol | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
7.23 | 39 Cr | 3.20 | 0.66 | 0.00 | — | — | 0.00 | |
25.45 | 39 Cr | 17.43 | 3.04 | 0.00 | 16.82 | 22.19 | 13.88 | |
0.91 | 39 Cr | 11.14 | 0.81 | 0.00 | 6.34 | 6.34 | 11.77 | |
19.39 | 39 Cr | 48.48 | 1.71 | 0.00 | 2.04 | 2.92 | 2.32 | |
5.41 | 38 Cr | 1082.00 | 0.55 | 0.00 | 0.24 | 3.32 | 0.41 | |
31.31 | 38 Cr | -4.37 | 0.85 | 0.00 | -19.78 | -4.27 | -9.62 | |
77.56 | 38 Cr | -20.20 | 0.48 | 0.00 | 1.03 | 1.75 | -2.37 |
Bearish
2
Neutral
6
Bullish
6
Bearish
13
Neutral
6
Bullish
27
Bearish
11
Neutral
0
Bullish
21
Investor Presentation
Veerhealth Care Ltd. submitted its investor presentation to BSE on 25‑Feb‑2026 under Regulation 30; the deck (posted on the company website) details business overview, USFDA OTC approval (June 2025), manufacturing expansion and export plans.
Investor Presentation
Veerhealth Care Ltd filed an investor presentation under Regulation 30 (25‑Feb‑2026) with BSE, disclosing USFDA OTC registration/approval, US registration details, manufacturing/expansion updates (Vapi, Veer Plast), product portfolio and website availability.
Investor Presentation
Veerhealth Care submitted an investor presentation to BSE under Regulation 30, available on its website, outlining its USFDA Drug (OTC) approval, Vapi facility expansion, export strategy (including US market) and product portfolio.
Investor Presentation
Veerhealth Care submitted an investor presentation to BSE on 25‑Feb‑2026 (also posted on its website) highlighting its USFDA‑approved OTC manufacturing facility, export readiness, product portfolio and expansion plans.
Veerhealth Care Limited is diversified in the pharmaceutical and personal care manufacturing sector, focusing on creating formulations of cosmetics and oral care products.
Since 2013, the company has expanded from infrastructure and finance into the pharma sector, clearly defining its scope towards cosmetics and personal care industries.
By leveraging ayurvedic expertise, the company aims to develop high-quality herbal products for various applications, utilizing traditional knowledge from its parent company.
The company's evolution from financial services to a diverse manufacturing portfolio indicates a strategic shift towards consumer health and wellness products.
Pharmaceuticals
Trading - Medium / Small
39 Cr
Low Risk
48.5
37.7
—
1.7
23.77
9.29
Sales CAGR
Profit CAGR
ROE
ROCE
